Featured Research

from universities, journals, and other organizations

New clinical trial to examine medication to treat social withdrawal in Fragile X and autism

Date:
July 25, 2011
Source:
Rush University Medical Center
Summary:
Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists.

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

Rush is the only site in Illinois and one of 21 hospitals in the U.S. participating in the trial for Fragile X. Fragile X syndrome is a neurodevelopmental disorder characterized by impaired social function, cognition and speech, as well as attention deficits and anxiety.

People with Fragile X, autism or autism spectrum disorders often display social impairment including social withdrawal and anxiety and have difficulty communicating and interacting with others. Although there are behavioral and psychological interventions, there are no approved medications for the treatment of social or communication difficulties in Fragile X, autism and autism spectrum disorders.

"The condition can be severely debilitating and this medication has the potential to play a much needed role in improving the core symptoms of fragile X syndrome and helping patients and their families achieve an improved quality of life," said Dr. Elizabeth Berry-Kravis, pediatric neurologist at Rush and principal investigator of the study.

The study is sponsored by Seaside Therapeutics, Inc, and will test the efficacy, safety and tolerability of the drug called STX209 (arbaclofen).

Racemic baclofen (mixture of arbaclofen and esbaclofen) is approved by the FDA to treat spasticity and stiff muscles due to cerebral palsy or other forms of brain or spinal cord injury, but arbaclofen, the more active form of baclofen, is not FDA approved.

"There is some evidence that the medication may help with social behaviors in people with developmental disabilities," said Berry-Kravis, who is a professor of pediatrics, neurology and biochemistry at Rush University.

Participants in the randomized, double-blind, placebo controlled phase III trial will be randomized to receive either the study drug, STX209, or a placebo. The clinical trial will include screening, treatment, withdrawal of medication, and a follow-up period. Subjects who complete the study may be eligible to enroll in a subsequent open-label study in which all subjects are treated with STX209.

STX209 has been studied in a previous small placebo-controlled trial in children and adults with fragile X syndrome and showed evidence of benefit for social withdrawal.

"Previous research has found that from one-quarter to one-half of people with fragile X have autism spectrum disorders," said Berry-Kravis.

"This trial is exciting, because it represents the culmination of 20 years work in fragile X research since discovery of the fragile X gene in 1991," said Kravis. "We're not expecting this to cure fragile X or autism, but it's a very important step in the development of new treatments."


Story Source:

The above story is based on materials provided by Rush University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush University Medical Center. "New clinical trial to examine medication to treat social withdrawal in Fragile X and autism." ScienceDaily. ScienceDaily, 25 July 2011. <www.sciencedaily.com/releases/2011/07/110720121933.htm>.
Rush University Medical Center. (2011, July 25). New clinical trial to examine medication to treat social withdrawal in Fragile X and autism. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2011/07/110720121933.htm
Rush University Medical Center. "New clinical trial to examine medication to treat social withdrawal in Fragile X and autism." ScienceDaily. www.sciencedaily.com/releases/2011/07/110720121933.htm (accessed April 16, 2014).

Share This



More Mind & Brain News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
App Fights Jet Lag With The Power Of Math

App Fights Jet Lag With The Power Of Math

Newsy (Apr. 13, 2014) Researchers at the University of Michigan have designed an app to fight jet lag by adjusting your body's light intake. Video provided by Newsy
Powered by NewsLook.com
Treatment Gaps Endangering Cops, Mentally Ill

Treatment Gaps Endangering Cops, Mentally Ill

AP (Apr. 10, 2014) As states slash funding for mental health services, police officers are interacting more than ever with people suffering from schizophrenia and other serious disorders of the mind. The consequences can be deadly. (April 10) Video provided by AP
Powered by NewsLook.com
Teen Drinking Rates Linked To Alcohol Mentions In Pop Music

Teen Drinking Rates Linked To Alcohol Mentions In Pop Music

Newsy (Apr. 9, 2014) A University of Pittsburgh study found pop music that mentions alcohol is linked to higher drinking rates among teens. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins